Introduction
The vascular system is the fi rst functionally developed organ system during ontogeny. The development of blood vessels starts with differentiation of mesodermal precursor cells toward endothelial cells (ECs), hematopoietic cells, and vascular smooth muscle cells. The fi rst vascular plexus in embryos is formed by de novo aggregation of hemangioblasts (vasculogenesis) . Thereafter, vessel growth mainly occurs by the sprouting of capillaries from preexisting vessels (angiogenesis; Risau, 1997; Carmeliet, 2000) . Endothelial sprouting is a complex process that involves the increase of vascular permeability, vessel wall disassembly, degradation of the basement membrane, migration and proliferation of ECs, and, fi nally, the formation of a capillary lumen. The newly formed sprouts are subsequently stabilized by formation of cellular junctions, extracellular matrix deposition, and recruitment of perivascular cells (Pepper, 2001; Jain, 2003) . Among other proteases, matrix metalloproteinases (MMPs) are required for proteolytic remodeling of the extracellular matrix. Degradation of the EC basement membrane, as well as cleavage of helical interstitial collagens, is rate limiting for endothe lial sprouting (Pepper, 2001; Seandel et al., 2001; Davis and Senger, 2005) .
Although angiogenic signaling through growth factors like VEGF or basic FGF and their receptors has been studied in great detail, the role of endothelial transcription factors orchestrating the angiogenic response is less well understood. Genetic approaches suggested that transcription factors of the hypoxiainducible factor, Ets, Gata, Hox, Hey, SCL/Tal, and Smad families are implicated in different stages of vascular development (Oettgen, 2001; Coultas et al., 2005) . Recently, an increasing body of evidence associated members of the Activator Protein-1 (AP-1) family of transcription factors either directly or by cooperation with aforementioned factors with angiogenic responses and/or programs Gerald et al., 2004; Zhang et al., 2004) . AP-1 consists of homo-or heterodimers of Jun (c-Jun, JunB, and JunD), Fos (c-Fos, FosB, Fra-1, and -2), and ATF (ATF-2, -3, -4, and ATFa) family members (Angel and Karin, 1991; Eferl and Wagner, 2003; Hess et al., 2004) . Although different Jun factors have been reported to regulate genes implicated in angiogenesis, like VEGF and MMPs Eferl and Wagner, 2003; Zhang et al., 2004) , a direct link between endothelial Jun proteins and angiogenesis has thus far remained questionable. When the different Jun members were deleted in mice, only JunB-defi cient embryos displayed vascular abnormalities and died between embryonic day (E)8.5 and E10 because of placental failure . Conditional gene targeting JunB is required for endothelial cell morphogenesis by regulating core-binding factor β
Results

Embryonic lethality caused by loss of JunB expression in ECs
JunB is expressed in ECs during vascular development (SchorppKistner et al., 1999) . To investigate the cell-autonomous function of JunB in ECs, we generated mice that lack JunB expression specifi cally in their ECs. Tie-2-Cre transgenic mice were crossed to junB −/fl ox mice to generate a junB −/∆ allele in ECs (junB −/∆ EC ). To better visualize ECs, the mice were crossed to Tie-2-lacZ reporter mice. The Cre-mediated deletion of the junB locus was detected by PCR analysis (unpublished data). Coexpression of JunB and the EC marker CD31 was confi rmed by immunofl uorescence staining of control embryos (Fig. 1 B) . In contrast, junB −/∆ EC embryos showed no JunB expression in blood vessels, whereas other cell types (e.g., neurons) retained JunB expression. These data confi rm the effi cient deletion of the fl oxed allele, specifi cally in ECs. Embryonic lethality was observed around E10 in junB −/∆ EC mice. The embryos were already severely retarded at E9.5 compared with controls ( Fig.  1 A) . Embryos had not yet turned and displayed enlarged pericardial sacs. At E10.5, control mice developed a highly organized vascular tree in the head region, whereas junB −/∆ EC embryos showed a disorganized vasculature with aberrantly branching and dilated vessels (Fig. 1 A) . Additionally, the yolk Figure 1 . Endothelium-specifi c deletion of junB disrupts vascular development. junB −/∆ EC embryos were generated by mating Tie-2-Cre/junB +/− and junB fl ox mice. (A) All embryos carried a Tie-2-lacZ transgene to visualize ECs by LacZ activity. Control embryos developed a normal vascular system, whereas junB −/∆ EC embryos were retarded at E9.5, had an enlarged pericardium, and showed a disorganized vasculature. At E10.5, when control embryos had developed a vascular tree in the cephalic region, junB −/∆ EC embryos showed hardly any capillary sprouting and dilated vessels. Highly branched vessel structures were formed in yolk sacs (ys) of control embryos at E10.5, whereas yolk sacs of junB −/∆ EC embryos showed only a primitive vascular plexus. (B) Colocalization of JunB and CD31 was observed by immunofl uorescence staining. Control embryos expressed JunB in ECs, whereas in junB −/∆ EC embryos JunB was expressed in neurons (asterisk), but was absent from CD31-positive blood vessels. (right) Schematic view of an embryo is given to indicate analyzed area (boxed region). Lu, lumen; nt, neural tube. Bars: (A) 250 μm; (B) 100 μm.
sacs of junB −/∆ EC embryos showed marked defects in vascular remodeling, as vessels formed only a primitive vascular plexus. In contrast, a hierarchically organized vessel structure developed in control mice (Fig. 1 A) . Interestingly, this phenotype closely resembled the vascular defects observed in the embryo proper of the complete junB knockout mice . However, vascularization of the placenta was not impaired in junB −/∆ EC mice (Fig. S1 , available at http://www. jcb.org/cgi/content/full/jcb.200605149). These data defi ne an important role for JunB in the endothelial lineage in vivo.
Capillary sprouting of aortic explants is severely impaired in JunB-defi cient mice
Because of the early embryonic death, it was diffi cult to investigate altered EC function in junB −/∆ EC mice. Therefore, we used a second transgenic mouse model with conditional inactivation of JunB. In Collagen1α2-Cre/junB −/∆ mice (junB −/∆ Coll ), effi cient recombination of the junB locus occurred in many cell types, as reported previously . In contrast to completely JunB-defi cient mice, these animals were viable because of the fact that the deletion of junB occurred at a later stage of embryonic development (around E14; unpublished data). Analysis of genomic DNA revealed complete junB deletion in aortic tissue and isolated primary ECs of junB −/∆ Coll mice (Fig. 2 A) . To prove loss of JunB expression on protein level, primary ECs were isolated from these mice. Expression of endothelial marker proteins was confi rmed by FACS analysis and immunofl uorescence staining for CD31, endoglin (CD105), VEGFR-2, or VE-cadherin ( Fig. 2 B and not depicted), demonstrating the isolation of a 94-98% pure population of ECs. Immunoblotting revealed that the JunB protein was indeed undetectable in junB −/∆ Coll ECs, whereas it was expressed in control ECs (Fig. 2 C) .
To investigate whether junB −/∆ Coll mice have a defect in blood vessel growth, mouse aortic ring assays were performed with explanted tissue of control or junB −/∆ Coll aortae (Fig. 2 D) . Within 7 d of explant culture, strong outgrowth of capillary sprouts from the aortic rings was observed in control (Fig. 2 D) or Tie-2-lacZ reporter mice. Staining for LacZ activity or immunofl uorescence staining for CD31 confi rmed that these sprouts originate from ECs and that they form a vessel lumen (Fig. S2 , A-E, available at http://www.jcb.org/cgi/content/full/ jcb.200605149). In contrast, junB −/∆ Coll rings showed nearly no capillary outgrowth (Fig. 2 D) . To exclude that the effect is solely caused by paracrine VEGF acting on ECs, aortic ring assays were performed in the presence of exogenously added recombinant VEGF. In control aortae, the addition of VEGF to the medium did not further increase the already strong sprouting activity (Fig. 2 E) , indicating that the VEGF levels in the medium are already in a saturation range. In junB −/∆ Coll explants, additional VEGF had no effect on sprout formation (Fig. 2 E) . Thus, VEGF is not the limiting factor for sprouting in this system, and JunB most likely induces capillary growth via other mechanisms. The capability of primary ECs to form tube-like structures was investigated upon cultivation on Matrigel (Fig. 3 A) . Control ECs formed capillary-like structures that connected to anastomosing networks within 18 h in culture. In sharp contrast, junB −/∆ Coll ECs largely failed to generate tubes, but instead formed cellular aggregates, even if cultured for longer time periods. Like in the aortic ring assay, addition of recombinant VEGF did not rescue the tube formation defect (unpublished data). Our fi nding was supported by the use of a second model involving JunB-defi cient transformed ECs, so-called endothelioma (END) cells that provide a model for activated embryonic endothelium (Reiss et al., 1998) . Control END cells formed tubelike structures and networks of EC cords very rapidly (within 6 h) on Matrigel (Fig. 3 A) . As observed for junB −/∆ Coll ECs, cord formation of JunB-defi cient END cells was drastically decreased (13% of the control cells), which was quantifi ed by counting interendothelial spaces (Fig. 3 C) . A similar phenotype was observed with END cells derived from junB fl ox/fl ox mice, in which the fl oxed allele was deleted by transduction of a retroviral Cre expression vector (junB ∆/∆; Fig. 3 A, bottom) . The fl oxed allele was effi ciently deleted ‫,)%09ف(‬ as revealed by FACS analysis for IRES-eGFP expression (unpublished data) and PCR amplifi cation of the recombined locus (Fig. 3 B) . To enhance vascular density, the aortic explants were cultured in medium containing 40 or 100 ng/ml recombinant VEGF. Under both conditions, vascular density was signifi cantly lower in junB −/∆ coll aortae compared with the controls. Error bars indicate the SD. *, P < 0.05.
Defective tube formation could be caused by a failure in proliferation; thus, the proliferation rate of control and junB −/∆ Coll ECs was determined by BrdU incorporation and subsequent FACS analysis, which revealed no considerable difference (Fig. 3 D) . Lateral migration was investigated by scratching EC monolayers and by monitoring wound closure after 24 and 48 h. A slight delay in wound closure was observed in JunB-defi cient cells after 48 h ( Fig. 3 E) ; however, these small differences in migration alone cannot account for the severe defects in tube formation (Fig. 3 A) . The expression levels of genes typically involved in angiogenesis were analyzed by RT-PCR. No differences in expression of angiopoietin-1 and -2 or their receptors tie-1 and -2 were observed. Decreased VEGF levels were found, but the main signaling receptor, VEGFR-2, was unaffected. In addition, similar levels of the AP-1 family members c-Jun, c-Fos, and ATF-2 were detected in control and JunB-defi cient ECs (unpublished data). Collectively, analysis of proliferation, migration, and expression of known angiogenic candidate genes did not reveal fi rst signs for a mechanism that could explain the phenotype of JunB-defi cient cells. Therefore, a systematic approach was chosen to compare the gene expression profi les of JunBdefi cient and control cells.
cDNA microarray analysis identifi es novel
JunB target genes
To search for target genes affected by the loss of JunB in the endothelium, large-scale comparative gene expression analysis was performed using cDNA microarray technology. JunB expression is highly up-regulated by hypoxia ( Fig. 4 B) ; thus, a combinatorial analysis of gene expression was performed in control and JunB-defi cient ECs cultured under normoxia or hypoxia. Under hypoxic conditions, 729 genes were upregulated in control cells, whereas the expression of 956 genes was repressed. However, by comparing the expression profi le of control with JunB-defi cient cells under hypoxic conditions, only 23 genes were up-regulated and 16 genes were repressed in a strictly JunB-dependent manner. The newly identifi ed JunBdependent genes (Table I) included transcription factors (CBFβ, Creb3l2, Pou6f1, Klf16, and FoxJ2) , factors involved in protein synthesis (Farsla, Aars, and Eif3s10), genes involved in intracellular traffi cking (Tram1, Kif5b, and Myo1D), genes involved in cytoskeletal architecture (Nestin, Rhophilin-2, and Tbcd), and genes regulating apoptosis (Diablo and Nix) and metabolism (Acsl4, Aldh1b1, Fdft1, and Tgm2).
CBF is induced by hypoxia in a JunB-dependent manner
Of the newly identifi ed JunB target genes, our attention was attracted by CBFβ. AP-1 and CBF factors physically interact in a transcriptional complex and transactivate common target genes (Selvamurugan et al., 1998; Hess et al., 2001) . CBFβ is the common partner of the Runt-related transcription factors (Runx). Real-time RT-PCR analysis confi rmed the results from the microarray analysis, showing a 3.3-fold induction of CBFβ under hypoxia, which was lost in junB −/− END cells, as well as in Cre-transduced junB ∆/∆ cells ( Fig. 4 A and not depicted). Induction of CBFβ correlated with that of JunB by hypoxia in END cells (Fig. 4 B) . To confi rm that CBFβ is a JunB target in vivo, bone marrow cells were isolated from control and JunBdefi cient mice. Indeed, CBFβ expression was considerably reduced (by 60%) in the absence of JunB, as determined by real-time RT-PCR and Western blot analysis (Fig. 4 C) . Moreover, immunofl uorescence staining was performed on embryo sections of junB −/∆ EC and control embryos. CBFβ expression colocalized with CD31-positive vessels in control embryos, whereas no CBFβ signal was detected in vessels of junB −/∆ EC embryos (Fig. 4 D) . To investigate whether CBFβ is a direct JunB target, the murine CBFβ promoter region was cloned and different fragments were fused to a luciferase reporter gene. Promoter analysis revealed three potential AP-1 binding sites (12-O-tetradecanoylphorbol-13-acetate-responsive elements [TREs] ) in the distal promoter region (nt −1,496 to −1,061) and one TRE and two cAMP-responsive elements (CREs) in (Fig. 4 E, top) . Coexpression of JunB with the dimerization partners ATF-2 or c-Fos further increased CBFβ promoter activity four-or eightfold induction, respectively, whereas expression of ATF-2 or c-Fos alone had no effect (Fig. 4 E, top) . The region containing the three distal TREs alone (nt −1,496 to −1,061) showed hardly any activity in this assay (Fig. 4 E, bottom) ; therefore, we hypothesized that JunB binding to the CBFβ promoter should take place at the proximal CREs and TRE. To fi nally prove the physical interaction of JunB with the CBFβ promoter, chromatin immunoprecipitation (ChIP) analysis was performed in ECs in the absence or presence of CoCl 2 . Primers were designed to amplify specifi c regions of the CBFβ promoter (P1, P2, and P3) that contain the TRE and CREs for potential binding of JunB. We found JunB binding at the proximal CREs and TRE (Fig. 4 F, P1 and P2 ). This binding was strongly enhanced in CoCl 2 -treated cells. In contrast, no interaction was observed at the three distal TREs (P3), confi rming the data of the luciferase reporter assay (Fig. 4 E) . To fi nd the dimerization partner of JunB regulating CBFβ expression, ChIP analysis was performed using antibodies against ATF-2, c-Fos, and Fra-1 that are expressed in ECs. We only detected a constitutive interaction of ATF-2 with the CBFβ promoter in uninduced and CoCl 2 -treated ECs (Fig. 4 F, bottom) . The binding occurred at the proximal CREs and TRE (P1), in the same region where JunB binding was detected. No ATF-2 binding was found at the three distal TREs. We detected no interaction of c-Fos or Fra-1 with the CBFβ promoter (unpublished data). These data The proximal fragment harboring only the proximal CRE and TRE elements (−1127/−251) shows a similar activity as the reporter with both distal and proximal CRE and TRE sites (−1496/−251). Expression of JunB induced the promoter, whereas ATF-2 or c-Fos had no effect. JunB in combination with either ATF-2 or c-Fos led to a strong transactivation of these two CBFβ promoter fragments, whereas promoter activity of the reporter containing solely the distal TRE elements (−1496/−1061) was hardly detectable. (F) ChIP analysis of the CBFβ promoter was performed using antibodies for JunB or ATF-2. Specifi c primer sets were used to discriminate promoter elements (P1, P2, and P3). JunB binding to the CBFβ promoter was detected at the proximal CRE and TRE (P1 and P2) and was strongly enhanced in ECs treated with 200 μM CoCl 2 for 4 h. Binding of ATF-2 also occurred at the proximal promoter region (P1), whereas no binding of JunB or ATF-2 was found at the distal TRE sites (P3). Error bars indicate the SD. *, P < 0.05. strongly suggest that either a JunB-JunB homodimer or a JunB-ATF-2 heterodimer regulates CBFβ expression in ECs in vivo.
CBF expression in JunB-defi cient ECs rescues tube formation defects
To determine whether CBFβ is functionally implicated in the tube-forming process of ECs, we attempted to rescue the phenotype. By retroviral gene transfer CBFβ, JunB, or empty control vector (Fig. S3 A, available at http://www.jcb.org/cgi/ content/full/jcb.200605149) were reintroduced into JunBdefi cient END cells. After culture in selective medium, >96% of the cells integrated the retroviral vector into their genome, as determined by FACS analysis for the coexpressed IRES-GFP reporter (Fig. S3 B) . Immunoblotting confi rmed strong expression of CBFβ or JunB in transduced cells (Fig. S3 C) . As expected, JunB-defi cient END cells transduced with empty vector did not form capillary-like structures when cultured on Matrigel (Fig. 5 A) . Tube formation was effi ciently rescued by reexpression of JunB in END cells (Fig. 5 A) . Most notably, CBFβ expression also rescued tube formation in JunBdefi cient cells (Fig. 5 A) . To quantify vascular organization in these experiments, the interendothelial spaces were counted, which revealed a signifi cant difference between the END cells transduced with empty vector and those transduced with CBFβ or JunB, respectively (Fig. 5 B) . These data underscore a functional implication of CBFβ in the morphogenic process downstream of JunB. 
Reduced collagenase activity and expression in JunB-defi cient ECs
To mechanistically explain the observed defects in sprouting and tube formation of JunB-defi cient cells, we studied the invasive capacity of control and JunB-defi cient ECs. The ECs were plated on type I collagen gel, and after 10-14 d control cells changed from polygonal to spindlelike morphology and invaded the gel underlying the monolayer. By focusing through the optical planes, cells underneath the monolayer were identifi ed that displayed long cellular protrusions and fi lopodia, indicating an invasive/angiogenic phenotype (Fig. 6 A) . In contrast, JunB-defi cient cells formed a monolayer on top of the collagen, but failed to invade deeper into the gel (Fig. 6 A) .
To investigate the molecular basis of impaired invasion, supernatants of control and junB −/∆ Coll ECs were analyzed for collagenolytic activity. In this assay, native helical collagen served as a substrate, which is cleaved only by MMP-8, -13, and -14. Supernatant of JunB-defi cient ECs revealed a 40% decrease in overall collagenase activity (Fig. 6 B) , suggesting that reduced collagenase activity accounts for the impaired EC sprouting. RT-PCR analysis revealed strongly reduced expression of not only MMP-13 but also MMP-2, a known JunB target gene (Bergman et al., 2003) , in JunB-defi cient ECs in comparison to control cells. In contrast, MMP-9 and -14 mRNA levels were not affected (Fig. 6 C) , whereas MMP-8 expression was not detectable in cells of both genotypes (unpublished data). The reduced expression of MMP-2 and -13 was confi rmed by real-time RT-PCR analysis (Fig. 6 D) . MMP-13 represents a well-documented common target of AP-1 and CBF transcription factors that can physically interact and cooperate in the transactivation of MMP-13 in osteoblastic cells (Selvamurugan et al., 1998; Hess et al., 2001 ). We were able to confi rm these fi ndings in ECs (Fig. S4 , available at http://www.jcb.org/cgi/ content/full/jcb.200605149).
The AP-1/CBF target gene MMP-13 is required for tube formation
To unequivocally determine the function of MMP-13 in this process, primary ECs were isolated from mmp-13 −/− mice (Stickens et al., 2004; Hartenstein et al., 2006 ) and applied in a tube formation assay. Indeed, MMP-13-defi cient ECs largely failed to form capillary-like networks on Matrigel (14% compared with control cells), confi rming an essential role of MMP-13 in tube formation in our model system (Fig. 7, A and B) . Finally, we investigated MMP-13 expression in JunB-defi cient END cells transduced with CBFβ. Although junB −/− END cells transduced with empty vector showed no MMP-13 expression, introduction of CBFβ strongly up-regulated MMP-13 expression (Fig. 7 C) . Together, these fi ndings suggest that the defects in tube formation and sprouting observed in JunB-defi cient ECs are a consequence of impaired CBFβ expression, resulting in reduced expression of proteases.
Discussion
Previously, we have reported critical functions for JunB in controlling cytokine-regulated mesenchymal-epidermal interactions in skin by regulating keratinocyte proliferation and differentiation in both a paracrine and autocrine manner (Florin et al., 2004b . Very recently, we could demonstrate an essential role for JunB in basal and hypoxia-mediated VEGF expression and tumor angiogenesis, implying a paracrine mechanism for fi broblast or tumor cell-derived VEGF acting on the endothelium (unpublished data). As JunB is also highly expressed in ECs, in this study we specifi cally addressed the ECintrinsic requirement of JunB and JunB-dependent genetic programs. Indeed, JunB deletion in the endothelial lineage using Tie-2-Cre mice resulted in severe vascularization defects in the yolk sac and embryo proper and early embryonic death, suggesting an EC-intrinsic role for JunB. Accordingly, sprout formation of JunB-defi cient aortic explants and capability of primary ECs lacking JunB to form capillary-like cords when cultivated on Matrigel was strongly impaired, even in the presence of excessive recombinant VEGF, excluding that limiting VEGF levels account for this phenotype.
In the search for JunB-dependent target genes implicated in EC morphogenesis, we focused on genes differentially expressed in JunB-defi cient ECs kept under normoxic or hypoxic conditions compared with control cells to mimic a physiological condition for angiogenesis induction. Applying stringent criteria for expression profi ling, 23 up-and 16 down-regulated genes were identifi ed to be dependent on JunB and hypoxia. These genes can functionally be grouped in cytoskeletal components, transcription factors, translational factors, and genes implicated in apoptosis, cellular traffi cking, or metabolism.
For example, the group of cytoskeletal genes includes nestin, which is an intermediate fi lament protein that is highly expressed in neuronal stem cells, but also in activated ECs. As nestin expression is down-regulated in quiescent ECs, it was recently designated as a specifi c marker for angiogenic ECs and probably a modulator of cytoskeletal dynamics in activated ECs (Mokry et al., 2004) . A second cytoskeletal gene found in our screen is rhophilin-2, which encodes a Rho-GTPase-binding protein that modulates Rho activity, and thereby infl uences rearrangement of the actin cytoskeleton (Peck et al., 2002) . Previously, it has been shown that Rho-mediated actin organization is essential for cord formation of angiogenic ECs (Hoang et al., 2004; Liu and Senger, 2004) . A second group of JunB target genes is comprised of transcriptional regulators, such as LBP-1a, which is a mammalian homologue of the grainyhead transcription factor family originally found in Drosophila melanogaster and implicated in BMP-4 signaling. Interestingly, LBP-1a-defi cient mice display a phenotype very similar to that of JunB knockout mice, as the embryos die at E10 and have severe defects in the vascularization of placenta and yolk sac (Parekh et al., 2004) . In summary, the physiological features of these identifi ed target genes imply that JunB is required for the transition from quiescent to angiogenic endothelium.
Yet, we concentrated our analysis on another transcriptional regulator found among the JunB-dependent genes, namely the CBFβ, which is the common heterodimerization partner of the Runx comprising the three α-subunits Runx-1 (CBFα-2 and AML-1), -2 (CBFα-1), and -3 (CBFα-3). The Runx-CBFβ dimer binds to a specifi c DNA sequence and, depending on the recruitment of coactivators or co-repressors, activates or suppresses the transcription of target genes, respectively (Blyth et al., 2005) .
Inactivation of the runx genes in mice revealed essential functions in defi nitive hematopoiesis (Runx-1), in bone formation (Runx-2), or in epithelial and neuronal development (Runx-3). Runx-1-defi cient embryos had a lower number of small capillaries in the hindbrain; moreover, vessels in the hindbrain, pericardium, and yolk sac showed less branching (Takakura et al., 2000) .
Deletion of the CBFβ subunit disrupted normal hematopoiesis and caused embryonic lethality between E12.5 and E13.5. Transgenic CBFβ expression in the hematopoietic system rescued embryonic lethality and revealed impaired bone formation in CBFβ-defi cient mice (Speck and Gilliland, 2002; Blyth et al., 2005) . Hemorrhages were observed in the cephalic and lumbar region of CBFβ-defi cient embryos starting at E10.5. This was associated with perivascular edema and cell death in areas of actively growing capillaries. It was hypothesized that CBFβ may play a role in certain aspects of vessel development, although this was not tested directly (Wang et al., 1996) . Moreover, Runx-1 or CBFβ are frequent targets of chromosomal translocation in humans, which account for 25% of adult acute myeloid leukemia. In junB −/∆ Coll mice, CBFβ expression was decreased in bone marrow, which is the major site of endogenous CBFβ expression in vivo. Interestingly, phenotypes of CBFβ-and JunB-deficient mice exhibit striking similarities. Mice with reduced JunB expression develop a leukemia-like disease (Passegue et al., 2001 ) and have defects in bone formation (Hess et al., 2003; Kenner et al., 2004) , providing further physiological evidence for a role of JunB in regulating CBFβ expression.
Our data point to an additional function of CBFβ in the hypoxia-response of ECs. ChIP analysis revealed that CBFβ is a direct target gene of JunB in ECs. We demonstrate that CBFβ is functionally important for EC morphogenesis, as reexpression of CBFβ in JunB-defi cient ECs rescued tube formation on Matrigel. CBFβ, Runx-1, and -2 expression was reported in ECs (Namba et In line with our fi ndings, a function of CBFβ in ECs has been proposed previously, as overexpression of a dominant-negative mutant of CBFβ inhibited EC tube formation in type I collagen gels (Namba et al., 2000) . Similarly, loss of Runx-1, or a truncated Runx-2 protein, perturbs tube formation on Matrigel (Iwatsuki et al., 2005; Sun et al., 2001) .
CBF and AP-1 are known to cooperate in the transactivation of the metalloproteinase MMP-13 (Selvamurugan et al., 1998; Porte et al., 1999; Hess et al., 2001 ). MMP-13 is an interstitial collagenase able to degrade native fi brillar collagens in the triple helical domain in vivo that is required for endochondral bone formation and homeostasis (Inada et al., 2004; Stickens et al., 2004) . Recent evidence points to a critical and specifi c function of MMP-13 derived from activated stromal cells and infl ammation-responsive hematopoietic cells at sites of tumor tissue (Egeblad and Werb, 2002; Mueller and Fusenig, 2004) and in the chick chorioallantoic membrane in response to angiogenic factors (Seandel et al., 2001; Zijlstra et al., 2004) . We provide experimental evidence that loss of EC-intrinsic MMP-13 expression caused by junB ablation and, consequently, impaired CBFβ expression results in diminished collagenolytic activity of JunB-defi cient ECs and failure in sprouting and tube formation. Accordingly, mmp-13 −/− ECs also exhibited strongly reduced tube formation on Matrigel, suggesting that loss of MMP-13 may account for the angiogenic defects in JunB-defi cient ECs. Reexpression of CBFβ in JunB-defi cient cells led them to regain MMP-13 expression and tube formation. Thus, our data provide strong evidence for a regulatory JunB-CBFβ-protease axis in the EC sprouting process. Interestingly, mmp-13 knockout mice display delayed enchondral ossifi cation and reduced vessel ingrowth into the primary ossifi cation center (Inada et al., 2004; Stickens et al., 2004) , presumably caused by the reduced bioavailability of VEGF. It was concluded that MMP-13 produced by chondrocytes might be critical for the release of matrix-bound VEGF. So far there exists only one study stressing an EC-intrinsic role for MMP-13 as an important effector of nitric oxide-activated EC migration (Lopez-Rivera et al., 2005) . Thus, our fi ndings underscore the importance of MMP-13 in EC function, which may also contribute to the phenotype of MMP-13-defi cient mice.
In conclusion, we demonstrate an essential cell-autonomous function of JunB in ECs and identify CBFβ as a novel JunB target. The fact that a common target of CBF and AP-1, MMP-13, is crucial for capillary-like tube formation suggests important tasks for CBFβ in diseased neovascularization such as cancer and retinopathy. Henceforth, it will be interesting to dissect not only the individual contribution of autocrine and paracrine pathways addressed by JunB but also JunB/CBFβ converging on commonly known, as well as yet to be defi ned, targets. It is conceivable that these pathways may prove to be a promising target for antiangiogenic therapy in the future.
Materials and methods
Transgenic mice
The generation of junB +/− (Schorpp- , junB fl ox (Kenner et al., 2004) , Tie-2-Cre (Constien et al., 2001 ), Collagen1α2-Cre (Florin et al., 2004a , and mmp13 −/− mice (Stickens et al., 2004) has been previously described. Tie-2-lacZ (Schlaeger et al., 1997) transgenic mice were provided by U. Deutsch (University of Berne, Berne, Switzerland). The Tie-2-Cre or Collagen1α2-Cre mice were crossed to junB +/− mice and their offspring were mated to junB fl ox/fl ox mice to obtain junB −/∆ mice. junB +/fl ox, junB +/∆, junB −/fl ox, or junB +/+ mice were used as controls. For genotyping, genomic DNA was isolated and PCR was performed for the junB locus as previously described (Schorpp-Kistner et al., 1999) . Embryos were fi xed and stained for LacZ activity, as previously described (Licht et al., 2004) . For image acquisition, a dissecting microscope (M 10; Leica) equipped with a PlanApo 1.0×/0.04 NA objective (Leica) and a digital camera (DXM1200; Nikon) were used. Images were processed with Photoshop CS software (Adobe).
All mice used in this study were housed in specifi c pathogen-free and light-, temperature-(21°C), and humidity-controlled (50-60% relative humidity) conditions. Food and water were available ad libitum. The procedures for performing animal experiments were in accordance with the principles and guidelines of the Arbeitsgemeinschaft der Tierschutzbeauftragten in Baden-Württemberg (offi cials for animal welfare) and were approved by the Regierungspräsidium Karlsruhe.
Cell culture and luciferase reporter gene assay END cells were established by infection of ECs derived from midgestation embryos with the N-TKmT retrovirus, as previously described (Reiss et al., 1998) . END cells expressed endothelial marker genes (VE-cadherin, CD31, CD105, and VEGFR-2), as determined by immunofl uorescence staining or FACS analysis, and were able to endocytose DiI-acetyl-LDL particles (CellSystems). For hypoxia treatment, END cells were placed in an incubator with 1.5% O 2 partial pressure (CB; Binder) for 16 h.
The murine CBFβ promoter (nt −1,496 to −251) was amplifi ed by PCR using the primers CBFβ1 and CBFβ2 (Table S1 , available at http://www.jcb.org/cgi/content/full/jcb.200605149). The promoter was ligated to a tata-luciferase reporter plasmid (van Dam et al., 1998) . F9 teratocarcinoma cells were cultured and transiently transfected as previously described (Hess et al., 2001) . 1 μg CBFβ promoter fused to the luciferase reporter gene was cotransfected with 0.5 μg AP-1 expression plasmids (JunB, c-Fos, and ATF-2 under control of the Rous sarcoma virus promoter) and 0.05 μg renilla-luciferase for normalization. Cells were lysed and luciferase activity was determined using the Dual-Luciferase reporter system (Promega) and a Sirius luminometer (Berthold).
Isolation of primary ECs
Microvascular ECs were isolated from mouse lungs using a magnetic cell separation method, as previously described (Dong et al., 1997) . In brief, magnetic beads (Dynabeads; Dynal) were coated with anti-CD31 antibodies (Mec13.3; BD Biosciences). Two mouse lungs of similar genotype were pooled, minced, and digested with collagenase A solution (Roche). Cells were incubated with anti-CD31-coated Dynabeads and separated in a magnetic fi eld. After washing away unbound cells, the beads were released by trypsin/EDTA treatment. Isolated ECs were analyzed for the expression of endothelial marker genes as described in Cell culture and luciferase reporter gene assay.
Mouse aortic ring assay
Aortic explants were prepared as previously described (Zhu and Nicosia, 2002) . Mouse aortae were dissected free from connective tissue, cut in 1-2-mm pieces using a scalpel, and washed in ice-cold DME. For each tissue explant, a drop of 40 μl rat type I collagen (Serva) was placed into a culture dish. Aortic rings were placed into the droplet with fi ne forceps. After polymerization of the gel, the dishes were fi lled with culture medium (see Isolation of primary ECs) supplemented with 40 or 100 ng/ml recombinant VEGF-A164 (R&D Systems). Capillary sprouting was quantifi ed in a semiquantitative manner by classifi cation of aortic rings from 1 (no capillary sprouting) to 4 (strong outgrowth reaching the margins of the collagen matrix). In each experiment, at least nine aortic rings of control and junB −/∆ Coll mice were scored, and the experiment was repeated four times.
In vitro angiogenesis and invasion assay
Matrigel (BD Biosciences) was mixed with an equal volume ice-cold DME. 150 μl Matrigel solution was poured into 48-well plates and incubated for at least 6 h at 37°C. 3.5 × 10 4 cells were seeded on top of the gel and incubated for 6-24 h. Capillary-like tube formation was quantifi ed by counting interendothelial spaces in three randomly chosen optical fi elds. Each assay was performed in triplicate.
For analysis of invasive capacity, ECs were seeded on a type I collagen gel and grown to confl uency. After incubation for 10 d, the invasion of EC into the underlying collagen gel was assessed by microscopic observation of different focus planes. For image acquisition, an inverse light microscope (DMIL; Leica) equipped with Plan Apo objectives (4×/0.1 NA and 10×/0.2 NA) and a DXM1200 digital camera were used. Images were processed with Photoshop CS software.
BrdU incorporation
Proliferation was assessed by BrdU incorporation and subsequent FACS analysis using the BrdU Flow kit (BD Biosciences) according to the instructions of the manufacturer. In brief, 10 5 ECs were seeded on 6-well plates and cultured for 24 h. Cells were incubated with medium containing BrdU for 2 h and subjected to the assay protocol.
Lateral migration assay
ECs were plated in 6-well dishes and grown to confl uency. The monolayer was wounded by scratching with a pipette tip and photographed. After 24 and 48 h, the wounded area was photographed again and the wound closure was measured using ImageJ software (National Institutes of Health).
Retroviral gene transfer
JunB or CBFβ coding sequences were amplifi ed by PCR using the primers junB1, junB2, CBFβ3, and CBFβ4 (Table S1 ). The fragments were inserted into the pMXpie vector. JunB-defi cient END cells were transduced with retroviral vectors as previously described (Cerwenka et al., 2000) . In brief, cellular supernatant containing viral particles was transferred to 8 × 10 4 END cells in 24-well plates. Cells were transduced by spin infection (3 h; 2,000 rpm) and thereafter cultured in selective media containing 3 μg/ml puromycin (Sigma-Aldrich). Effi ciency of retroviral infection was determined by FACS analysis of GFP reporter gene expression.
cDNA microarray analysis
Total RNA was extracted from END cells cultured under normoxic or hypoxic conditions (1.5% O 2 for 16 h) using TRIZOL reagent as suggested by the manufacturer (Invitrogen). A collection of 15,247 sequences from embryonic cDNA libraries was used to generate the 15K NIA cDNA microarray. Details on probe labeling, hybridization, data acquisition, and analysis were previously described (Florin et al., 2004b) .
RT-PCR analysis
Total RNA was isolated from mouse tissue or cultured ECs using peqGold RNApure reagent (PEQLAB) according to the instructions of the manufacturer. RNA was reverse transcribed using AMV reverse transcriptase (Promega). cDNA was used for semiquantitative RT-PCR or quantitative real-time RT-PCR using Absolute QPCR SYBR Green mix (ABgene) and a thermal cycler (iCycler; BioRad Laboratories) controlled by MyiQ software (BioRad Laboratories). Primer sequences for MMPs were previously described . For primer sequences for β-tubulin, HPRT, CBFβ5 and -6, and JunB 3 and 4 see Table S1 .
Western blot analysis
Whole-cell extracts or nuclear extracts were prepared as previously described (Andrecht et al., 2002) . Proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane. Immunodetection was performed using an enhanced chemiluminescence system (Perkin Elmer Life Science) and the following primary antibodies: anti-JunB (1:500; N17; Santa Cruz Biotechnology, Inc.), anti-RCC1 (1:500; BD Biosciences), anti-CBFβ (1:500; E20; Santa Cruz Biotechnology, Inc.), and anti-HSC70 (1:10,000; Noventa).
Collagenase activity assay
Collagenolytic activity in supernatants of EC cultures was determined using the Collagenase Activity Assay kit (CHEMICON International, Inc.) according to the instructions of the manufacturer. Equal numbers of control and JunB-defi cient cells were seeded and cultured for 24-48 h. 100 μl of the supernatant were then subjected to the assay protocol.
Immunofl uorescence staining
Cryosections were fi xed with acetone at −20°C and stained at RT, as previously described ). An epifl uorescence microscope (DMLB; Leica) equipped with PlanApo objectives (10×/0.4 NA, 20×/0.7 NA, 40×/0.85 NA, and 63× oil/1.3 NA) was used. A DXM1200 digital camera was used for documentation, and images were processed with Photoshop CS software. The primary antibodies used were CD31 (BD Biosciences), JunB (210; Santa Cruz Biotechnology, Inc.), and CBFβ (E20; Santa Cruz Biotechnology, Inc.). The secondary antibodies used were goat anti-rat-Alexa Fluor 488 (Invitrogen) and goat anti-rabbit-Cy3 (Dianova).
ChIP Assay
A ChIP kit (Millipore) was used according to the instructions of the manufacturer. The antibodies used (all from Santa Cruz Biotechnology, Inc.) were JunB (c11), ATF-2 (c19), Fra-1 (N17), and c-Fos (4). For primer sequences for the amplifi cation of the CBFβ promoter see Table S1 .
In brief, 2.5 × 10 6 END cells were incubated with 200 μM CoCl 2 for 4 h. Cells were cross-linked in 1% formaldehyde for 20 min at RT. Cells were washed and sonicated using a Bioruptor device (Diagenode). Immunoprecipitation was performed using protein A-Agarose. After washing, protein-DNA complexes were eluted and cross-links were reversed. Proteins were digested by proteinase K and DNA was extracted using QIAquick spin columns (QIAGEN).
Statistical analysis
The SD is indicated by error bars. Unpaired two-tailed t tests were performed using Sigma Plot 8.0 software. Signifi cance was assumed for P values (P < 0.05; indicated by asterisks). Table S1 shows details on PCR primer sequences. Fig. S1 shows the investigation of placental development, Fig. S2 shows the microscopic evaluation of aortic ring assays, Fig. S3 shows the validation of retroviral gene transfer, and Fig. S4 shows mmp-13 promoter analysis in ECs.
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